Tanvex BioPharma and TaiMed Biologics form a business alliance to offer efficient CDMO services
Exhibitor: TAIMED BIOLOGICS INC.
Date: 2022-06-14
Booth No.: R305
Tanvex BioPharma (6541) and TaiMed Biologics (4147) jointly announced on June 14, 2022 to form a business alliance to offer CDMO services in the development and manufacturing of Antibody-Drug Conjugates (ADC) and Bispecific Antibodies (BsAb).
Both companies already have full R&D and CDMO capabilities. Leveraging both parties’ experienced R&D teams, advanced technologies, and state-of-the-art GMP manufacturing facilities, the alliance will be able to offer high-quality CDMO services at competitive pricing from bench to commercialization.
Tanvex is an experienced developer and manufacturer of biosimilars. Tanvex’s laboratory in Taiwan is well established for cell line development, clone selection, and early part of process development. TaiMed is a proven developer and manufacturer of biologics for HIV treatment, having one protein drug, Trogarzo, already approved by the FDA and EMA. With 4x2000L single use bioreactors and corresponding downstream processing, TaiMed’s GMP facility in Taiwan has the capacity to manufacture both clinical and commercial stage monoclonal antibodies from Tanvex and other clients. The facility recently passed the US FDA pre-approval inspection (PAI) with no 483 observations.
This business alliance will synergistically unleash both companies’ capabilities and capacities to the next level. In this arrangement, Tanvex will focus on the initial stage of gene sequencing, cell line development, and process development; TaiMed will focus on technology transfer, scale-up, and full scale manufacturing and testing.
More Exhibitor's Press Release
- Guard Patch-AIOT wearable system and platform COMMUNICATION AND BIOLOGIC INTEGRATED CIRCUITS (CBIC) LAB, NCKU / 2022-06-25
- AIOT for Prevention of Cardiovascular Disease COMMUNICATION AND BIOLOGIC INTEGRATED CIRCUITS (CBIC) LAB, NCKU / 2022-06-25
- Guard Patch-Your Health Technology Co., Ltd. COMMUNICATION AND BIOLOGIC INTEGRATED CIRCUITS (CBIC) LAB, NCKU / 2022-06-25
- FDA Approves GoldenBiotech IND of Antroquinonol for Relapsed AML GOLDEN BIOTECHNOLOGY CORP. / 2022-06-23
- GoldenBiotech Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinono GOLDEN BIOTECHNOLOGY CORP. / 2022-06-23
- Third-party Study Report: Pump Particle Shedding Evaluation LEVITRONIX GMBH TAIWAN BRANCH / 2022-06-23
- Third-party Study Report: Investigation of Shear Stress Exerted on CHO Cell by Different Pump System LEVITRONIX GMBH TAIWAN BRANCH / 2022-06-23
- Third-party Study Report: Investigation of Shear Stress Exerted on Proteins by Different Pump System LEVITRONIX GMBH TAIWAN BRANCH / 2022-06-23
- Twist Signs Antibody Discovery Collaboration with MediSix Therapeutics to Develop T-cell Therapies TWIST BIOSCIENCE / 2022-06-22
- Twist Launches Rapid Turnaround Panels to Advance R&D in MRD Detection in Cancer Screening TWIST BIOSCIENCE / 2022-06-22
- Twist Bioscience Launches High Throughput Antibody Production Platform TWIST BIOSCIENCE / 2022-06-22
- Envirotainer introduces the RAP for the future – part of the Releye® series ENVIROTAINER AB / 2022-06-22
- Lo.Li. Pharma Awards 2022 LO.LI. PHARMA INTERNATIONAL SRL / 2022-06-21
- Lo.Li. Pharma Case History: "The world-famous supplements Made in Italy" LO.LI. PHARMA INTERNATIONAL SRL / 2022-06-21
- 20 Years of Lo.Li. Pharma Group LO.LI. PHARMA INTERNATIONAL SRL / 2022-06-20
- GoldenBiotech is Partnering at BIO-2022, San Diego GOLDEN BIOTECHNOLOGY CORP. / 2022-06-20
- ACRO Biomedical launches the new product iMist Collagen Mist Spray in BIO Asia-Taiwan 2022 ACRO BIOMEDICAL CO., LTD. / 2022-06-15
- TAV VACUUM FURNACES company presentation TAV VACUUM FURNACES SPA / 2022-06-14
- Exosomes and Microvesicles: Concentration, sizing and phenotyping using NTA MALVERN PANALYTICAL / 2022-06-14
- TAIMED JOINS THE 2022 BIO INTERNATIONAL CONVENTION IN SAN DIEGO AND 2022 BIO ASIA TAIWAN IN TAIPEI TAIMED BIOLOGICS INC. / 2022-06-14